Madrigal Pharmaceuticals (MDGL)

Executive Summary

Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis (MASH). Its lead product, Rezdiffra (resmetirom), was approved by the FDA in March 2024 for the treatment of MASH with moderate-to-advanced liver fibrosis (F2-F3), making it the first and only approved therapy for this high-unmet-need indication. The company is capitalizing on its first-mover advantage by expanding the label through ongoing clinical trials, including a Phase 3 study in non-cirrhotic NAFLD (MAESTRO-NAFLD-1) and a Phase 2 combination study in MASH. With increasing commercial uptake and potential label expansion, Madrigal is well-positioned to capture a significant share of the growing MASH market, which represents a multi-billion-dollar opportunity. However, competition from other pipeline agents and reimbursement challenges remain key risks.

Upcoming Catalysts (preview)

• Q2 2026MAESTRO-NAFLD-1 Phase 3 top-line results (NAFLD without NASH)75% success
• H2 2026Potential FDA approval for compensated cirrhosis (F4) based on MAESTRO-NASH cirrhosis data50% success
• Q2 2026Q1 2026 earnings update highlighting commercial sales trajectory90% success